CYduct Diagnostics logo

CYduct Diagnostics(OTC) CYDX

Market Cap$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-38%
1 Year+14%
1 Month-50%
$0.50
+0.00%
+0.00Today
CYduct Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 0.502026-10-16
CYduct Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.502026-10-09
1 month-50%USD 1.002026-09-16
3 month-81.48%USD 2.702026-07-17
Year to date+146.18%USD 0.202025-12-31
1 year+14.18%USD 0.442025-10-10
3 year-1.96%USD 0.512023-10-16
5 year-37.5%USD 0.802021-10-15
Since inception-100%USD 15,151,515,151.522007-01-16

CYduct Diagnostics Financials at a Glance

Market Cap

$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$70.37K

Net Income (TTM)

-$207.40K

EPS (TTM)

-$0.04

P/E Ratio

-11.14

Dividend

$0.00

Beta (Volatility)

-0.12 (Low)

Price

$0.50

Volume

6

Open

$0.50

Previous Close

$0.50

Daily Range

$0.50 - $0.50

52-Week Range

$0.20 - $2.90

Estimated Earnings Date

N/A

CYDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CYduct Diagnostics

CYduct Diagnostics, Inc. is a medical instrument company focused on engineering and commercializing innovative technologies for health diagnostics and management. Established in 1986 and headquartered in Westport, Connecticut, the company offers a diverse range of medical devices and methodologies aimed at improving patient outcomes.

Products and Services
  • Specialized breast endoscopy systems and camera solutions
  • Comprehensive endoscopic instruments for various surgical specialties
  • Instrumentation tailored for veterinary applications
Growth Outlook
  • Recent quarterly revenue increased to $28,811, reflecting a strong demand for medical devices
  • Gross profit margin improved to 66.3% in the latest quarter
  • Expansion into veterinary applications opens new market opportunities
Financial Highlights
  • Trailing twelve months (TTM) revenue of $88,000, showing growth potential
  • Net income of $47,084 in the latest quarter, indicating a positive trend
  • Operating cash flow improved significantly, reaching $5,960 in Q3
CYduct Diagnostics, Inc. operates in the medical devices sector, providing essential tools for healthcare professionals. The company's product offerings include advanced endoscopic systems and instruments that cater to both human and veterinary medicine. With a focus on innovation, CYduct aims to enhance diagnostic capabilities and therapeutic interventions. The growth outlook for CYduct is promising, as evidenced by the recent increase in quarterly revenue and improved gross profit margins. The expansion into veterinary applications presents an opportunity to tap into a growing market, potentially driving further revenue growth. Financially, the company has shown resilience, with a notable increase in net income in the latest quarter. The positive operating cash flow indicates effective management of resources, which is crucial for sustaining operations and funding future growth initiatives. Overall, CYduct Diagnostics, Inc. is positioned to capitalize on its innovative product offerings and market expansion strategies, making it an intriguing prospect for potential investors.
AI Generated • Oct 10, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Dominick L. Gatto

Website

www.cyductdx.com

Headquarters

Westport, CT 06880, US

CYDX Financials

Key Financial Metrics (TTM)

Gross Margin

62.32%

Operating Margin

-220.10%

Net Income Margin

-294.73%

Return on Equity

8.29%

Return on Capital

N/A

Return on Assets

-690.85%

Earnings Yield

-8.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.14M

Volume

6

Avg. Volume

242.092

Financials (TTM)

Gross Profit

$43.85K

Operating Income

-$154.89K

EBITDA

-$154.89K

Operating Cash Flow

$11.50K

Capital Expenditure

-$4.00

Free Cash Flow

$11.49K

Cash & ST Invst.

$7.22K

Total Debt

$707.90K

CYduct Diagnostics Performance Analysis

CYduct Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 119,33926.9%
20242024-06-30USD 84,484-29.2%
20252025-06-30USD 70,687-16.3%
20262026-06-30USD 70,371-0.4%
CYduct Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-61.6%
Q22025-12-310.4%
Q32026-03-31147.3%
Q42026-06-3025.3%
CYduct Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD -0.0913.2%
20242024-06-30USD -0.08-13.3%
20252025-06-30USD -0.08-1.7%
20262026-06-30USD -0.04-52.6%
CYduct Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-303.8%
Q22025-12-319.1%
Q32026-03-314.4%
Q42026-06-30124.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$28.81K

+19.4%

Gross Profit

$19.09K

+26.6%

Gross Margin

66.27%

N/A

Market Cap

$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$856.87K

N/A

Employees

3

N/A

Net Income

$47.08K

+149.5%

EBITDA

$60.70K

+173.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$7.22K

+496.3%

Total Debt

$707.90K

-0.8%

Accounts Receivable

$12.32K

-34.1%

Inventory

$10.49K

-41.0%

Long Term Debt

$627.90K

+0.0%

Short Term Debt

$80.00K

-6.4%

Return on Assets

-6.91%

N/A

Return on Invested Capital

36.26%

N/A

Free Cash Flow

-$370.00

+76.4%

Operating Cash Flow

-$369.00

+76.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TBIOTelesis Bio, Inc.
$0.04+0.00%
ESMCEscalon Medical Corp.
$0.17-5.56%
PHMBPharmaCom BioVet, Inc.
$0.00+0.00%
EDXCEndexx Corporation
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About CYDX

What is the current price of CYduct Diagnostics?

CYduct Diagnostics is trading at $0.50 per share.

What is the 52-week range for CYduct Diagnostics?

Over the past 52 weeks, CYduct Diagnostics has traded between $0.20 and $2.90.

How much debt does CYduct Diagnostics have?

As of the most recent reporting period, CYduct Diagnostics reported total debt of $707.90K.

How much cash does CYduct Diagnostics have on hand?

CYduct Diagnostics reported $7.22K in cash and cash equivalents in its most recent financial results.

What is CYduct Diagnostics’s dividend yield?

CYduct Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services